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Tumor lysis syndrome is an oncologic emergency that can present with variable symptoms and 
is truly a laboratory-based diagnosis without pathognomonic clinical findings. The classical 
teaching is to consider this diagnosis in cancer patients undergoing chemotherapy. We present 
the case of a 66-year-old female with newly diagnosed metastatic liver adenocarcinoma, not on 
chemotherapy, who was diagnosed with spontaneous tumor lysis syndrome. Cognizance of this 
syndrome and associated laboratory findings are paramount to diagnosis and rapid intervention. 
[Clin Pract Cases Emerg Med. 2019;3(4):398–400.]
INTRODUCTION
Tumor lysis syndrome (TLS) is an oncologic emergency 
seen in patients with rapidly proliferating hematologic 
malignancies following exposure to systemic chemotherapy. 
It is a metabolic disorder characterized by hyperuricemia, 
hyperkalemia, hypocalcemia, and hyperphosphatemia, which 
can result in acute kidney injury, cardiac arrhythmias, and 
central nervous system toxicity. Spontaneous TLS (STLS) 
is rare and occurs in the absence of cytotoxic therapy. It 
is characterized by spontaneous cellular death in rapidly 
proliferating malignancies. STLS in patients with solid 
cancers is associated with a high mortality.1 We present a 
case of a woman recently diagnosed with metastatic colon 
adenocarcinoma who presented with STLS.
CASE REPORT
A 66-year-old female with past medical history of 
hypertension, hyperlipidemia, and diabetes mellitus presented 
to the emergency department (ED) with subacute weakness 
and dyspnea. Five weeks prior to this presentation, she was 
seen in the ED for abdominal pain and dyspnea and was 
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found to have large, bilateral pleural effusions and anemia. 
Extensive further work-up revealed a diagnosis of stage 
IV, poorly differentiated adenocarcinoma of the transverse 
colon. Imaging revealed diffuse large lymphadenopathy 
throughout the abdomen, retroperitoneum, and mediastinum 
with multiple pulmonary nodules. She underwent an 
open extended right hemicolectomy with ileostomy as 
well as resection of the jejunum due to tumor invasion. 
Thoracentesis was performed and she was eventually 
discharged home to follow up with oncology for discussions 
about immunotherapy or chemotherapy. 
At the current ED visit, the patient’s vitals were as 
follows: blood pressure 121/39 millimeters of mercury, pulse 
rate of 88 beats per minute, respiratory rate of 20 breaths per 
minute, and an oxygen saturation of 98% on three liters of 
oxygen via nasal cannula. Physical examination was pertinent 
for an ill-appearing female with mild jaundice, abdominal 
distention with mild tenderness, and decreased breath 
sounds with rales in the bilateral lower lung fields. A chest 
radiograph showed bilateral pleural effusions. The complete 
blood count was unremarkable. The complete metabolic 
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What do we already know about this 
clinical entity? 
Tumor lysis syndrome (TLS) is an 
oncologic emergency identified by 
lab abnormalities: hyperkalemia, 
hyperphosphatemia, hyperuricemia, 
hypocalcemia, and acute kidney injury.
What makes this presentation of disease 
reportable? 
TLS may occur spontaneously, but 
typically it occurs in the setting of 
hematologic malignancies. Spontaneous 
TLS in solid tumors is rare.
What is the major learning point? 
The classic lab abnormalities of TLS 
should prompt consideration of this 
complication in any oncology patient, 
regardless of concomitant chemotherapy. 
How might this improve emergency 
medicine practice? 
Early recognizance of TLS can lead 
to rapid management, mitigation of 
complications, and improved emergency 
medical care.
panel demonstrated hyponatremia, hyperkalemia, uremia, 
acute kidney injury, and transaminitis (Table). Given the new 
acute kidney injury and hyperkalemia, there was suspicion 
for STLS. Additional diagnostics were obtained and revealed 
hypocalcemia, hypermagnesemia, hyperphosphatemia, and 
hyperuricemia (Table). Electrocardiogram demonstrated 
minimal changes in T-wave morphology as well as a slight 
increase in QRS duration. Review of the patient’s chart 
showed that all of the laboratory abnormalities were new in 
comparison to four weeks prior. 
A diagnosis of STLS was made in this patient with 
metastatic, poorly differentiated adenocarcinoma, who had 
not been initiated on systemic chemotherapy. Intravenous 
crystalloids, rasburicase, and treatment for acute hyperkalemia 
with calcium gluconate, insulin, dextrose, kayexalate, and 
sodium bicarbonate were initiated. After consulting the renal 
and oncology teams, the patient was admitted. Given the poor 
prognosis, the patient declined dialysis and further invasive 
measures. Her status was changed to comfort measures only 
and she died two days later. 
DISCUSSION
TLS can be therapy-related (cytotoxic therapy) or 
spontaneous (no exposure to cytotoxic therapy). TLS is more 
commonly seen in patients with hematologic malignancies 
compared to solid malignancies, due to increased proliferation 
rates and sensitivity to cytotoxic therapy.1-4 Solid tumors with 
a large tumor burden are at increased risk of TLS. STLS, 
which occurs in the absence of cytotoxic therapy, is more rare 
and most often seen in hematologic malignancies with high 
proliferation rates, such as acute leukemia and aggressive 
lymphomas, such as Burkitt lymphoma. 
One retrospective review found that STLS occurred in 
1.1% of patients with hematologic malignancy and acute renal 
failure.4 The rate of STLS in patients with solid malignancies 
is even lower, with the true prevalence remaining uncertain 
due to a paucity of literature comprised mainly of case 
reports.4 It has been described in patients with metastatic 
and advanced malignancies including small cell lung cancer, 
cholangiocarcinoma, hepatocellular carcinoma, and only 
two other cases of colon adenocarcinoma.1,3-5 The laboratory 
abnormalities outlined in the Cairo-Bishop definition of TLS 
include hyperuricemia, hyperkalemia, hyperphosphatemia, 
and hypocalcemia, either outside the reference range or a 
25% change from baseline.2 Potential complications of these 
metabolic abnormalities include acute kidney injury, cardiac 
arrhythmias, and seizures.1-4 
There is a 20-50% mortality rate in TLS occurring in solid 
tumors if undiagnosed, or diagnosed too late.6 Spontaneous 
development of TLS in solid tumors reflects large tumor 
burden and likely portends an even higher mortality. Timely 
recognition and intervention following a diagnosis of STLS is 
vital. Management consists of intravenous hydration, correction 
of electrolyte abnormalities, and treatment of hyperuricemia, 
which can lead to obstructive uropathy. Allopurinol can be used 
prophylactically in patients at high risk for TLS, but should not 
be used for hyperuricemia in acute TLS.5 Acute hyperuricemia 
in TLS or STLS can be treated with rasburicase, a recombinant 
urate oxidase enzyme that catalyzes uric acid to allantoin, or 
hemodialysis. Patients should have strict monitoring of urine 
output as persistent oliguria may be an additional indication for 
hemodialysis, along with hyperkalemia and hyperuricemia. 
Our patient had been recently diagnosed with metastatic 
colon adenocarcinoma with diffuse metastases. We believe the 
heavy tumor burden and rapid proliferative rate increased her risk 
of developing STLS. 
CONCLUSION
Consideration of a diagnosis of TLS was historically 
reserved for patients with the classic lab abnormalities 
who were undergoing chemotherapy. Reports of STLS in 
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both hematologic and solid malignancies are increasing in 
the literature. Many of these patients will first present to 
the ED and it is pertinent for the emergency physician to 
recognize this oncologic emergency. Striking electrolyte 
imbalances and acute kidney injury in any cancer patient 
ought to prompt consideration of STLS, as the associated 
complications can be life-threatening. 
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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Component Value Reference range
White blood cells 9.7 4.0-11.0 k/mm3
Hemoglobin 11.4 11.7-15.5 Gm/dL
Hematocrit 36.9 35.7-45.8%
Platelet count 473 150-460 k/mm3
INR 1.2 0.9-1.1
Prothrombin time 12.6 9.7-12.2 seconds
Sodium 123 133-145 mmol/L
*Potassium 7.7 3.6-5.2 mmol/L
Chloride 87 98-107 mmol/L
Bicarbonate 16 22-29 mmol/L
Anion gap 20 4-17
Glucose 137 70-99 mg/dL 
(fasting)
BUN 79 8-23 mg/dL
Creatinine 6.4 0.5-1.0 mg/dL
*Calcium, Ionized 1.02 1.13-1.32 mmol/L
Magnesium 2.4 1.3-1.9 mEq/L
LDH 544 94-250 units/L
Alkaline 
phosphatase
882 35-104 units/L
AST 81 0-32 units/L
ALT 36 0-33 units/L
Bilirubin, total 5.9 0-1.2 mg/dL
Lactate 1.7 0.5-2.2 mmol/L
Troponin T Quant <0.01 0.0-0.09 ng/mL
Nt-ProBNP 3,029 0-125 pg/mL
Haptoglobin 334 30-200 mg/dL
*Uric acid 23.9 1.6-7.6 mg/dL
*Phosphorus 10.1 2.5-4.5 mg/dL
*Laboratory abnormalities listed in the Cairo-Bishop definition 
 of tumor lysis syndrome (TLS). Creatinine ≥1.5x upper limit of 
normal meets criteria for clinical TLS, along with the defined 
laboratory changes (2). 
k, kilogram; mm3, cubic millimeter; gm, gram; dL, deciliter; INR, 
international normalized ratio; mmol, millimole; L, liter; mg, milligram; 
BUN, blood urea nitrogen; mEq, milliequivalent; LDH, lactate 
dehydrogenase; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; ng, nanogram; mL, milliliter; pg, picogram.
Table. Laboratory values of patient with tumor lysis syndrome.
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